Article | Published:

A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A

Abstract

The adenoviral oncoprotein E1A induces progression through the cell cycle by binding to the products of the p300/CBP and retinoblastoma gene families. A new cellular p300/CBP-associated factor (P/CAF) having intrinsic histone acetylase activity has been identified that competes with E1A. Exogenous expression of P/CAF in HeLa cells inhibits cell-cycle progression and counteracts the mitogenic activity of E1A. E1A disturbs the normal cellular interaction between p300/CBP and its associated histone acetylase.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Moran, E. Curr. Opin. Genet. Dev. 3, 63–70 (1993).

  2. 2

    Dyson, N. & Harlow, E. Cancer Surv. 12, 161–195 (1992).

  3. 3

    Chrivia, J. C. et al. Nature 365, 855–859 (1993).

  4. 4

    Kwok, R. P. et al. Nature 370, 223–226 (1994).

  5. 5

    Eckner, R. et al. Genes Dev. 8, 869–884 (1994).

  6. 6

    Arany, Z., Sellers, W. R., Livingstone, D. M. & Eckner, R. Cell 77, 799–800 (1994).

  7. 7

    Arany, Z., Newsome, D., Oldread, E., Livingston, D. M. & Eckner, R. Nature 374, 81–84 (1995).

  8. 8

    Lundblad, J. R., Kwok, R. P., Laurance, M. E., Harter, M. L. & Goodman, R. H. Nature 374, 85–88 (1995).

  9. 9

    Arias, J. et al. Nature 370, 226–229 (1994).

  10. 10

    Lee, J. S. et al. Genes Dev. 9, 1188–1198 (1995).

  11. 11

    Banister, A. J. & Kouzarides, T. EMBO J. 14, 4758–4762 (1995).

  12. 12

    Dai, P. et al. Genes Dev. 10, 528–540 (1996).

  13. 13

    Kamei, Y. et al. Cell 85, 403–414 (1996).

  14. 14

    Rochette-Egly, C., Fromental, C. & Chambon, P. Genes Dev. 5, 1200–1211 (1990).

  15. 15

    Struhl, K. Cell 50, 841–846 (1987).

  16. 16

    Engelberg, D., Klein, C., Martinetto, H., Struhl, K. & Karin, M. Cell 77, 381–390 (1994).

  17. 17

    Georgakopoulos, T. & Thireos, G. EMBO J. 11, 4145–4152 (1992).

  18. 18

    Berger, S. L. et al. Cell 70, 251–265 (1992).

  19. 19

    Horiuchi, J., Silverman, N., Marcus, G. A. & Guarente, L. Molec. cell. Biol. 15, 1203–1209 (1995).

  20. 20

    Berger, S. L., Cress, W. D., Cress, A., Triezenberg, S. J. & Guarente, L. Cell 61, 1199–1208 (1990).

  21. 21

    Marcus, G. A., Silverman, N., Berger, S. L., Horiuchi, J. & Guarente, L. EMBO J. 13, 4807–4815 (1994).

  22. 22

    Georgakopoulos, T., Gounalaki, N. & Thireos, G. Molec. gen. Genet. 246, 723–728 (1995).

  23. 23

    Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. J. molec. Biol. 215, 403–410 (1990).

  24. 24

    Adams, M. D., Soares, M. B., Kerlavage, A. R., Fields, C. & Venter, J. C. Nature Genet. 4, 373–380 (1993).

  25. 25

    Candau, R. et al. Molec. cell. Biol. 16, 593–602 (1996).

  26. 26

    Turner, B. M. Cell 75, 5–8 (1993).

  27. 27

    Wolffe, A. P. Trends biochem. Sci. 19, 240–244 (1994).

  28. 28

    Bownell, J. E. et al. Cell 84, 843–851 (1996).

  29. 29

    Haynes, S. R. et al. Nucleic Acids Res. 20, 2063 (1992).

  30. 30

    Hopp, T. P. et al. Biotechnology 6, 1205–1210 (1988).

  31. 31

    Harlow, E. D. & Lane, D. Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press, New York, 1988).

  32. 32

    Giordano, T., Howard, T. H., Coleman, J., Sakamoto, K. & Howard, B. H. Expl. Cell Res. 192, 193–197 (1991).

  33. 33

    Ogryzko, V. V., Hirai, T. H., Shih, C. E. & Howard, B. H. J. Virol. 68, 3724–3732 (1994).

  34. 34

    Minucci, S. et al. Molec. cell. Biol. 14, 360–372 (1994).

  35. 35

    Hayes, J. J., Pruss, D. & Wolffe, A. P. Proc. natn. Acad. Sci. U.S.A. 91, 7817–7821 (1994).

  36. 36

    Brownell, J. E. & Allis, C. D. Proc. natn. Acad. Sci. U.S.A. 92, 6364–6368 (1995).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.